Greg Mulholland – 2016 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Greg Mulholland on 2016-02-09.
To ask the Secretary of State for Health, when he plans to announce a decision on access to Translarna after the NICE Highly Specialised Technology Committee meeting on 17 February 2016.
George Freeman
The National Institute for Health and Care Excellence (NICE) is currently evaluating Translarna (ataluren) for the treatment of Duchenne muscular dystrophy through its highly specialised technology programme. The publication date for NICE’s final guidance is to be confirmed.
NHS England has advised that it is in constructive discussions with the pharmaceutical company about the development of a managed access agreement for Translarna and a progress update will be given at the next NICE Evaluation Committee meeting on 17 February 2016.
In the absence of guidance from NICE, it is for commissioners to make decisions on whether to fund medicines based on an assessment of the available evidence.
